Symphony Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/6l320adb1v5kagw9e6ffhu27.pdf

Key Takeaways


The Summer Shock: What Happened in Q2

Bakeri: "All because of weak summer. Nothing because of demand. The demand is because of the summer, the inventory is also because of the summer. That's all. The sentiment is also because of the summer. And one good month and this entire sentiment and inventory, everything can change. One good month, not even a one good summer."

RTY Portfolio: The Structural Hedge


Core Air Cooling: Defending Leadership

Kumar: "If this portfolio becomes a significant share of our total numbers, then at the GM level, maybe there is 1% or 2% point kind of impact. But at the absolute value level, this is going to be very clearly accretive."

International Subsidiaries: Clean-up in Progress


Margins & Financial Health


Guidance & Commitments

CommitmentSpecificsTimeline
Channel inventory normalizationMindset and stock levels to settle closer to historical meansBy end of Q3 FY26
GSK China IPR receiptRemaining ~₹23 crores expectedDecember quarter (Q3 FY26)
GSK China loan repayment~₹27 crores outstanding to be fully paid offEnsuing quarters
Pathway recoveryLegal steps pursued; charge created on promoter/company real estateOngoing (₹4 cr recovered in Oct)
Divestment (Mexico, Australia)Information memorandum submitted; LOIs received; NDAs signedNo timeline (process underway)
Production readinessScalability and operational agility built for demand surgeAhead of next summer

Key Metrics

MetricQ2 FY26
Standalone revenue₹155 cr, down from ₹259 cr in Sept '24
Standalone EBITDA₹27 cr, down from ₹72 cr
Standalone PAT₹28 cr, down from ₹67 cr
Standalone EBITDA marginDeclined mainly on account of operating deleverage
Consolidated revenue (continuing ops)₹163 cr, down from ₹289 cr
Consolidated EBITDA (continuing ops)₹25 cr, down from ₹76 cr
Consolidated PAT (continuing ops)₹25 cr
Consolidated PAT (total)₹19 cr
H1 FY26 standalone revenue₹384 cr
H1 FY26 standalone PAT~₹65 cr, down from ₹136 cr
Round-the-year product contribution~21% of Q2 top line, ~26% of trailing 12 months
Treasury (surplus funds)₹577 cr as on 30th Sept '25, versus ₹685 cr previously
Interim dividend₹1 per share (50%), total payout ~₹14 cr in H1
GSK China revenue₹32 cr, up from ₹25 cr
IMPCO Mexico revenue₹17 cr, up from ₹10 cr
Climate Holdings (Australia) revenue₹35 cr, up from ₹30 cr
Discontinued ops PATnegative ₹6 cr, improved from negative ₹14 cr in Sept '24
Channel inventory (end of Q2)Slightly higher than normal 25–30% of season sales